Top

Published in:

01-02-2017

Psychotropic drug dispensing in people with and without cancer in France

Authors: Pierre Verger, Sébastien Cortaredona, Marie Tournier, Dominique Rey, Marc-Karim Bendiane, Patrick Peretti-Watel, Hélène Verdoux

Published in: Journal of Cancer Survivorship | Issue 1/2017

Abstract

Purpose

To compare annual and monthly prevalence of psychotropic drug (PD) dispensing and the number and duration of psychotropic treatment episodes among people with and without cancer over a 2-year follow-up.

Methods

We studied the following two cohorts of adult patients affiliated with the National Health Insurance Fund (NHIF): cancer patients followed for 2 years after diagnosis and individuals without cancer matched to cancer patients. Using information about anxiolytic, hypnotic, antidepressant, and antipsychotic dispensing in community pharmacies, we applied conditional log-binomial regressions to estimate adjusted relative risks for monthly dispensing of PDs.

Results

Annual prevalence of PD dispensing—all categories included—among cancer patients was significantly higher for almost all the categories we studied than among individuals without cancer. Monthly prevalence of anxiolytic/hypnotic dispensing started to rise several months before diagnosis and peaked immediately after. Among patients with cancer and their matched controls, treatment duration exceeded 1 month for hypnotics in 40 and 35 %, respectively (p < 0.01), and 3 months for anxiolytics in 23 and 23 % (p = 0.8); it was less than 6 months for antidepressants in 76 and 75 % (p = 0.5).

Conclusions

Prevalence of psychotropic treatment was higher among cancer patients than among persons without cancer. Psychotropic treatment duration was not in line with recommendations for significant fractions of cancer patients or their controls.

Implications for cancer survivors

Training of health professionals involved in cancer supportive care should be reinforced and specific guidelines developed to help them address psychological distress of cancer survivors.

Available only for authorised users

Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71. doi:10.1093/annonc/mdt301.CrossRefPubMed

Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17(Suppl 8):viii15–23. doi:10.1093/annonc/mdl983.PubMed

Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006;12(5):432–43.CrossRefPubMed

Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24(32):5101–4. doi:10.1200/JCO.2006.09.2700.CrossRefPubMed

Bredart A, Kop JL, Griesser AC, Fiszer C, Zaman K, Panes-Ruedin B, et al. Assessment of needs, health-related quality of life, and satisfaction with care in breast cancer patients to better target supportive care. Ann Oncol. 2013;24(8):2151–8. doi:10.1093/annonc/mdt128.CrossRefPubMed

Jacobsen PB, Donovan KA, Trask PC, Fleishman SB, Zabora J, Baker F, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer. 2005;103(7):1494–502. doi:10.1002/cncr.20940.CrossRefPubMed

Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D, et al. Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study. Br J Cancer. 2007;96(6):868–74. doi:10.1038/sj.bjc.6603626.CrossRefPubMedPubMedCentral

Desplenter F, Bond C, Watson M, Burton C, Murchie P, Lee AJ, et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51. doi:10.1038/bjc.2012.364.CrossRefPubMedPubMedCentral

Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:57–71. doi:10.1093/jncimonographs/lgh014.CrossRef

10.

Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74. doi:10.1016/S1470-2045(11)70002-X.CrossRefPubMed

11.

Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–32. doi:10.1016/S1470-2045(13)70244-4.CrossRefPubMed

12.

Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7. doi:10.1002/pon.3056.CrossRefPubMed

13.

Reece JC, Chan YF, Herbert J, Gralow J, Fann JR. Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer. Gen Hosp Psychiatry. 2013;35(4):376–81. doi:10.1016/j.genhosppsych.2013.03.017.CrossRefPubMed

14.

Caruso R, Grassi L, Nanni MG, Riba M. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393. doi:10.1007/s11920-013-0393-0.CrossRefPubMed

15.

Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26. doi:10.1016/j.genhosppsych.2007.10.008.CrossRefPubMed

16.

Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356(9238):1326–7. doi:10.1016/S0140-6736(00)02821-X.CrossRefPubMed

17.

Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17(1):529. doi:10.1007/s11920-014-0529-x.CrossRefPubMed

18.

Derogatis LR, Feldstein M, Morrow G, Schmale A, Schmitt M, Gates C, et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44(5):1919–29.CrossRefPubMed

19.

Goldberg RJ, Mor V. A survey of psychotropic use in terminal cancer patients. Psychosomatics. 1985;26(9):745–8 . doi:10.1016/S0033-3182(85)72803-4.51CrossRefPubMed

20.

Jaeger H, Morrow GR, Carpenter PJ, Brescia F. A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen Hosp Psychiatry. 1985;7(4):353–60.CrossRefPubMed

21.

Stiefel FC, Kornblith AB, Holland JC. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65(4):1048–53.CrossRefPubMed

22.

Farriols C, Ferrandez O, Planas J, Ortiz P, Mojal S, Ruiz AI. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag. 2012;43(5):945–52. doi:10.1016/j.jpainsymman.2011.05.010.CrossRef

23.

de Bock GH, Musters RF, Bos HJ, Schroder CP, Mourits MJ, de Jong-van den Berg LT. Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20(7):1533–40. doi:10.1007/s00520-011-1242-5.CrossRefPubMed

24.

Sanjida S, Janda M, Kissane D, Shaw J, Pearson S-A, DiSipio T et al. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016:n/a-n/a. doi:10.1002/pon.4048.

25.

Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life—a population-based study. Psychooncology. 2013;22(3):506–14. doi:10.1002/pon.3059.CrossRefPubMed

26.

Khan NF, Ward AM, Watson E, Rose PW. Consulting and prescribing behaviour for anxiety and depression in long-term survivors of cancer in the UK. Eur J Cancer. 2010;46(18):3339–44. doi:10.1016/j.ejca.2010.07.035.CrossRefPubMed

27.

Pearson SA, Abrahamowicz M, Srasuebkul P, Buckley NA. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiol Drug Saf. 2015;24(6):600–9. doi:10.1002/pds.3753.CrossRefPubMed

28.

Bouhnik AD, Bendiane MK, Cortaredona S, Sagaon Teyssier L, Rey D, Berenger C, et al. The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open. 2015;5(3):e005971. doi:10.1136/bmjopen-2014-005971.CrossRefPubMedPubMedCentral

29.

National Cancer Institute. Cancer epidemiology in mainland France: incidence and mortality. National Cancer Institute. 2014. http://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers. Accessed 1 Feb 2015.

30.

Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256–65. doi:10.1002/pds.1912.CrossRefPubMed

31.

Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43. doi:10.1016/S0140-6736(12)60240-2.CrossRefPubMed

32.

Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–61. doi:10.1002/pst.433.CrossRefPubMed

33.

WHO Collaborating Centre for Drug Statistics Methodology: about the ATC/DDD system. Norwegian Institute of Public Health. 2007. http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system. . Accessed 1 Feb 2015.

34.

Bocquier A, Cortaredona S, Verdoux H, Sciortino V, Nauleau S, Verger P. Social inequalities in new antidepressant treatment: a study at the individual and neighborhood levels. Ann Epidemiol. 2013;23(3):99–105. doi:10.1016/j.annepidem.2012.12.008.CrossRefPubMed

35.

Etchepare F, Sanglier T, Andre M, Verdoux H, Tournier M. Antidepressant treatment patterns in younger and older adults from the general population in a real-life setting. Int J Geriatr Psychiatry. 2014;29(9):928–35. doi:10.1002/gps.4081.CrossRefPubMed

36.

Tournier M, Crott R, Gaudron Y, Verdoux H. Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatr Scand. 2013;127(5):365–72. doi:10.1111/acps.12035.CrossRefPubMed

37.

Verdoux H, Cougnard A, Thiebaut A, Tournier M. Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. Pharmacopsychiatry. 2011;44(3):96–101. doi:10.1055/s-0031-1271686.CrossRefPubMed

38.

Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health. 2013;13:1030. doi:10.1186/1471-2458-13-1030.CrossRefPubMedPubMedCentral

39.

Grolleau A, Cougnard A, Begaud B, Verdoux H. Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey. L’Encéphale. 2008;34(4):352–9. doi:10.1016/j.encep.2007.07.011.CrossRefPubMed

40.

Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83. doi:10.1111/j.1440-1819.2007.01778.x.CrossRefPubMed

41.

Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454. doi:10.1002/14651858.CD005454.pub2.

42.

Smith AB, King M, Butow P, Luckett T, Grimison P, Toner GC, et al. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psychooncology. 2013;22(11):2557–64. doi:10.1002/pon.3323.CrossRefPubMed

43.

Mazzocato C, Stiefel F, Buclin T, Berney A. Psychopharmacology in supportive care of cancer: a review for the clinician: II. Neuroleptics Support Care Cancer. 2000;8(2):89–97.CrossRefPubMed

44.

Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better?—a systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21(1):1–10.CrossRefPubMed

45.

Howell D, Oliver TK, Keller-Olaman S, Davidson JR, Garland S, Samuels C, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol. 2014;25(4):791–800. doi:10.1093/annonc/mdt506.CrossRefPubMed

46.

French National Authority for Health. Strategies of stopping benzodiazepine treatments: stakes and ways. French National Authority for Health. 2015. http://www.has-sante.fr/portail/jcms/c_747367/n7-focus. Accessed 1 Feb 2015.

47.

Richards D. NHS clinical knowledge summaries. Evid Based Dent. 2009;10(4):118–9. doi:10.1038/sj.ebd.6400690.CrossRefPubMed

48.

Jardin M, Bocquier A, Cortaredona S, Nauleau S, Millon C, Savard-Chambard S, et al. Potentially inappropriate prescriptions for the elderly: a study of health insurance reimbursements in southeastern France. Rev Epidemiol Sante Publique. 2012;60(2):121–30. doi:10.1016/j.respe.2011.10.004.CrossRefPubMed

49.

Anthierens S, Pasteels I, Habraken H, Steinberg P, Declercq T, Christiaens T. Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: family physicians’ attitudes toward benzodiazepine prescribing. Can Fam Physician. 2010;56(11):e398–406.PubMedPubMedCentral

50.

French National Authority for Health. Guide—chronic disease status 30. French National Authority for Health. 2011. http://www.has-sante.fr/portail/jcms/c_645938/fr/tumeur-maligne-affection-maligne-du-tissu-lymphatique-ou-hematopoietique. Accessed 1 Feb 2015.

51.

Holland JC, Andersen B, Breitbart WS, Compas B, Dudley MM, Fleishman S, et al. Distress management. J Natl Compr Cancer Netw. 2010;8(4):448–85.

52.

National Institute for Health and Clinical Excellence. NICE clinical guideline CG90: the treatment and management of depression in adults. National Institute for Health and Clinical Excellence. 2009. https://www.nice.org.uk/guidance/cg90. Accessed 1 Feb 2015.

53.

National Institute for Health and Clinical Excellence. NICE clinical guideline CG91: depression in adults with chronic physical health problem: recognition and management. National Institute for Health and Clinical Excellence. 2009. https://www.nice.org.uk/guidance/cg91. Accessed 1 Feb 2015.

54.

Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609–19. doi:10.1016/S0140-6736(09)60879-5.CrossRefPubMed

55.

Mayo Clinic Staff. Diseases and conditions: adjustment disorders. Mayo Clinic. 2014. http://www.mayoclinic.org/diseases-conditions/adjustment-disorders/basics/tests-diagnosis/con-20031704. Accessed 20 Jul 2016.

56.

Vaidya R, Sood R, Karlin N, Jatoi A. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):9–11. doi:10.1159/000330814.CrossRefPubMedPubMedCentral

57.

Linden W, MacKenzie R, Rnic K, Marshall C, Vodermaier A. Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories. Support Care Cancer. 2015;23(5):1391–9. doi:10.1007/s00520-014-2492-9.CrossRefPubMed

58.

Fiszer C, Dolbeault S, Sultan S, Bredart A. Prevalence, intensity, and predictors of the supportive care needs of women diagnosed with breast cancer: a systematic review. Psychooncology. 2014;23(4):361–74. doi:10.1002/pon.3432.CrossRefPubMed

Title: Psychotropic drug dispensing in people with and without cancer in France
Authors: Pierre Verger
Sébastien Cortaredona
Marie Tournier
Dominique Rey
Marc-Karim Bendiane
Patrick Peretti-Watel
Hélène Verdoux
Publication date: 01-02-2017
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 1/2017
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-016-0569-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for cancer survivors

Please log in to get access to this content

Other articles of this Issue 1/2017

Examining the prevalence of metabolic syndrome among overweight/obese African-American breast cancer survivors vs. matched non-cancer controls

Learning the landscape: implementation challenges of primary care innovators around cancer survivorship care

Factors influencing implementation of a survivorship care plan—a quantitative process evaluation of the ROGY Care trial

Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

Evaluation and treatment of insomnia in adult cancer survivorship programs

Keynote webinar | Spotlight on antibody–drug conjugates in cancer